Sporadic inclusion-body myositis and hereditary inclusion-body myopathies: Current concepts of diagnosis and pathogenesis

Current Opinion in Rheumatology

Volumn 10, Issue 6, 1998, Pages 530-542

  Askanas, Valerie ^a   Engel, W King ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; IMMUNOGLOBULIN; PREDNISONE; PROTEIN PRECURSOR; TESTOSTERONE CIPIONATE;

ADULT; AGED; AGING; ALZHEIMER DISEASE; CLINICAL ARTICLE; FEMALE; GENE SEQUENCE; GENETIC DISORDER; HUMAN; INCLUSION BODY MYOSITIS; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE CELL; MYOPATHY; OXIDATIVE STRESS; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

AGING; AUTOIMMUNITY; HUMANS; MUSCLE FIBERS; MUSCULAR DISEASES; MYOSITIS, INCLUSION BODY; OXIDATIVE STRESS;

EID: 0031768071     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199811000-00005     Document Type: Review

References (103)

1. Yunis EJ, Samaha FJ: inclusion-body myositis. Lab Invest 1971, 25:240-248.
2. Askanas V, Engel WK: New advances in the understanding of sporadic inclusion-body myositis and hereditary inclusion-body myopathies. Curr Opin Rheumatol 1995, 7:486-496.
3. Askanas V, Engel WK: Newest approaches to diagnosis and pathogenesis of sporadic inclusion-body myositis and hereditary inclusion-body myopathies, including molecular-pathologic similarities to Alzheimer disease. In Inclusion-body Myositis and Myopathies. Edited by Askanas V, Serratrice G, Engel WK. Cambridge: Cambridge University Press; 1998:3-78. Detailed review of IBM, including many illustrations and description of various hereditary forms.
4. Askanas V, Engel WK, Alvarez RB: Light- and electronmicroscopic localization of β-amyloid protein in muscle biopsies of patients with inclusion-body myositis. Am J Pathol 1992, 141:31-36.
5. Askanas V, Alvarez RB, Engel WK: β-amyloid precursor epitopes in muscle fibers of inclusion-body myositis. Ann Neurol 1993, 34:551-560.
6. Villanova M, Kawai M, Lubke U, Oh SJ, Perry G, Six J, et al.: Rimmed vacuoles of inclusion-body myositis and oculopharyngeal muscular dystrophy contain amyloid precursor protein and lysosomal markers. Brain Res 1993, 603:343-347.
7. Sarkozi E, Askanas V, Johnson SA, Engel WK, Alvarez RB: β-amyloid precursor protein mRNA is increased in inclusion-body myositis muscle. NeuroReport 1993, 4:815-818.
8. Askanas V, Engel WK, Bilak M, Alvarez RB, Selkoe DJ: Twisted tubulofilaments of inclusion-body myositis muscle resemble paired helical filaments of Alzheimer brain and contain hyperphosphorylated tau. Am J Pathol 1994, 144:177-187.
9. Mirabella M, Alvarez RB, Bilak M, Engel WK, Askanas V: Difference in expression of phosphorylated tau epitopes between sporadic inclusion-body myositis and hereditary inclusion-body myopathies. J Neuropathol Exp Neurol 1996, 55:774-786.
10. Askanas V, Engel WK, Yang C-C, Alvarez RB, Lee VM-Y, Wisniewski T: Light and electron microscopic immunolocalization of presenilin 1 in abnormal muscle fibers of patients with sporadic inclusion-body myositis and autosomal-recessive inclusion-body myopathy. Am J Pathol 1998, 152:889-895. First demonstration that a novel protein, mutations of which are responsible for familial AD, plays a role in pathogenesis of human muscle disease.
11. Askanas V, Engel WK: New advances in inclusion-body myositis. Curr Opin Rheumatol 1993, 5:732-741.
12. Schlesinger I, Soffer D, Lossos A, Meiner Z, Argov Z; inclusion-body myositis: atypical clinical presentations. Eur Neurol 1996, 36:89-93.
13. Coquet M, Coquet O, Ferrer X, Julien J, Vital C: Uncommon clinicopathologic forms of sporadic inclusion-body myositis: report of 4 cases. In Inclusion-body Myositis and Myopathies. Edited by Askanas V, Serratrice G, Engel WK. Cambridge: Cambridge University Press; 1998:126-136.
14. Riminton DS, Chambers ST, Parkin PJ, Pollock M, Donaldson IM: inclusion-body myositis presenting solely as dysphagia. Neurology 1993, 43:1241-1243.
15. Shapiro J, DeGirolami U, Martin S, Goyal R: Inflammatory myopathy causing pharyngeal dysphagia: a new entity. Ann Otol Rhinol Laryngol 1996, 105:331-335.
16. Kula RW, Engel WK, Line BR: Scanning for soft-tissue amyloid. Lancet 1977, i:92-93.
17. Askanas V, Engel WK, Alvarez RB, Frangione B, Ghiso J, Vidal R: Unusual pathologic features of sporadic inclusion-body myositis (s-IBM) accompanied by muscle blood-vessel amyloidosis in an African-American patient with cardiac amyloidosis, homozygous for the transthyretin (TTR) IIe-122 allele [abstract]. Ann Neurol 1998, 44:460.
18. Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS, Buxbaum JN: Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 1997, 336:466-473.
19. Engel WK, Haginoya K, Alvarez RB, Sabetian K, Bajoghli M, Askanas V: Sporadic inclusion-body myositis (s-IBM) in an HTLV-I-positive Iranian Muslim [abstract]. Neurology 1997, 48:124.
20. Cupler EJ, Leon-Monzon M, Miller J, Semino-Mora C, Anderson TL, Dalakas MC: inclusion-body myositis in HIV-1 and HTLV-1 infected patients. Brain 1996, 119:1887-1893.
21. Engel WK, Askanas V: Treatment of inclusion-body myositis and hereditary inclusion-body myopathy with reference to pathogenic mechanisms: personal experience. In Inclusion-body Myositis and Myopathies. Edited by Askanas V, Serratrice G, Engel WK. Cambridge: Cambridge University Press; 1998:351-382.
22. Abarbanel JM, Lichtenfeld Y, Zirkin H, Louzon Z, Osimani A, Farkash P, Herishanu Y: inclusion-body myositis in post-poliomyelitis muscular atrophy. Acta Neurol Scand 1988, 78:81-84.
23. Dalakas MC, Illa I, Leon-Monzon M: Viruses, immunodeficiency, and inclusion-body myositis. In Inclusion-body Myositis and Myopathies. Edited by Askanas V, Serratrice G, Engel WK. Cambridge: Cambridge University Press; 1998:275-290.
24. Felice KJ, Grunnet ML: inclusion-body myositis associated with a severe unilateral levodopa-responsive upper extremity tremor. Muscle Nerve 1996, 19:787-789.
25. Jensen ML, Wieting M, Andary MT, Fankhauser MJ, Jones MJ: inclusion-body myositis and transitional cell carcinoma of the bladder: significant resolution of symptoms after tumor excision. Arch Phys Med Rehabil 1997, 78:327-329.
26. Alexander JA, Huebner CJ: Hepatitis C and inclusion-body myositis. Am J Gastroenterol 1996, 91:1845-1847.
27. Ytterberg SR, Roelofs RI, Mahowald ML: inclusion-body myositis and renal cell carcinoma: report of two cases and review of the literature. Arthritis Rheum 1993, 36:416-421.
28. Koffman BM, Rugiero M, Dalakas MC: Immune-mediated conditions and antibodies associated with sporadic inclusion-body myositis. Muscle Nerve 1998, 21:115-117.
29. Mastaglia FL, Phillips BA, Zilko P: Treatment of inflammatory myopathies. Muscle Nerve 1997, 20:651-664.
30. Oddis CV: Therapy for myositis. Curr Opin Rheumatol 1993, 5:742-748.
31. Sayers ME, Chou SM, Calabrese LH: inclusion-body myositis: analysis of 32 cases. J Rheumatol 1992, 19:1385-1389.
32. Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K: Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 1997, 48:712-716.
33. Griggs RC, Rose M: Evaluation of treatment for sporadic inclusion-body myositis. In Inclusion-body Myositis and Myopathies. Edited by Askanas V, Serratrice G, Engel WK. Cambridge: Cambridge University Press; 1998:331-350.
34. Engel WK, Cunningham GG: Rapid examination of muscle tissue: an improved trichrome method for fresh-frozen biopsy sections. Neurology 1963, 13:919-923.
35. Eisen A, Berry K, Gibson S: inclusion-body myositis (IBM): myopathy or neuropathy? Neurology 1983, 33:1109-1114.
36. Lindberg C, Oldfors A, Hedström A: inclusion-body myositis: peripheral nerve involvement. Combined morphological and electrophysiological studies on peripheral nerves. J Neurol Sci 1990, 99:327-338.
37. Schröder JM, Molnar M: Mitochondrial abnormalities and peripheral neuropathy in inflammatory myopathy, especially inclusion-body myositis. Mol Cell Biochem 1997, 174:277-281.
38. Luciano CA, Dalakas MC: inclusion-body myositis: no evidence for a neurogenic component. Neurology 1997, 48:29-33.
39. Oldfors A, Moslemi A-R, Fyhr I-M, Holme E, Larsson N-G, Lindberg C: Mitochondrial DNA deletions in muscle fibers in inclusion-body myositis. J Neuropathol Exp Neurol 1995, 54:581-587. This article is an important study of mitochondrial DNA deletions and analysis of cytochrome C negative and ragged-red fibers in sporadic IBM.
40. Santorelli FM, Sciacco M, Tanji K, Shanske S, Vu TH, Golzi V, et al.: Multiple mitochondrial DNA deletions in sporadic inclusion-body myositis: a study of 56 patients. Ann Neurol 1996, 39:789-795. Detailed analysis of multiple mitochondrial DNA deletions in 56 patients.
41. Oldfors A, Moslemi A-R, Holme E, Lindberg C: Mitochondrial alterations in sporadic inclusion-body myositis. In Inclusion-body Myositis and Myopathies. Edited by Askanas V, Serratrice G, Engel WK. United Kingdom: Cambridge University Press; 1998:306-317.
42. Desnuelle C, Paquis V, Paul R, Engel WK, Saunières A, Alvarez RB, Askanas V: Mitochondrial DNA analysis in muscle of patients with sporadic inclusion-body myositis and hereditary inclusion-body myopathy. In Inclusion-body Myositis and Myopathies. Edited by Askanas V, Serratrice G, Engel WK. Cambridge: Cambridge University Press; 1998:318-328. First demonstration that mitochondrial DNA deletions are not present in h-IBM.
43. Mendell JR, Sahenk Z, Gales T, Paul L: Amyloid filaments in inclusion-body myositis. Arch Neurol 1991, 48:1229-1234.
44. Askanas V, Engel WK, Alvarez RB: Enhanced detection of congo-red-positive amyloid deposits in muscle fibers of inclusion-body myositis and brain of Alzheimer disease using fluorescence technique. Neurology 1993, 43:1265-1267.
45. Askanas V, Engel WK, Mirabella M: Idiopathic inflammatory myopathies: inclusion-body myositis, polymyositis, and dermatomyositis. Curr Opin Neurol 1994, 7:448-456.
46. Askanas V, Alvarez RB, Mirabella M, Engel WK: Use of anti-neurofilament antibody to identify paired-helical filaments in inclusion-body myositis. Ann Neurol 1996, 39:389-391. New method to identify IBM paired-helical filaments without the use of electron-microscopy.
47. Askanas V, Serdaroglu P, Engel WK, Alvarez RB: Immunocytochemical localization of ubiquitin in inclusion-body myositis allows its light-microscopic distinction from polymyositis. Neurology 1992, 42:460-461.
48. Prayson RA, Cohen ML: Ubiquitin immunostaining and inclusion-body myositis: study of 30 patients with inclusion-body myositis. Hum Pathol 1997, 28:887-892.
49. Murakami N, Ihara Y, Nonaka I: Muscle fiber degeneration in distal myopathy with rimmed vacuole formation. Acta Neuropathol 1995, 89:29-34.
50. Ikeuchi T, Asaka T, Saito M, Hajime T, Higuchi S, Tanaka K, et al.: Gene locus for autosomal recessive distal myopathy with rimmed vacuoles maps to chromosome 9. Ann Neurol 1997, 41:432-437.
51. Mitrani-Rosenbaum S, Argov Z, Blumenfeld A, Seidman CD, Seidman JG: Hereditary inclusion-body myopathy maps to chromosome 9p1-q1. Hum Mol Genet 1996, 5:159-163. First description of linkage to chromosome 9p1-q1 in quadriceps sparing autosomal-recessive IBM among Iranian Jews.
52. Askanas V: New developments in hereditary inclusion-body myopathies. Ann Neurol 1997, 41:421-422.
53. Argov Z, Tiram E, Eisenberg I, Sadeh M, Seidman CE, Seidman JG, et al.: Various types of hereditary inclusion-body myopathies map to chromosome 9p1-q1. Ann Neurol 1997, 41:548-551.
54. Middleton LT, Christodoulou K, Askanas V, Engel WK, McFerrin J, Kyriakides T, et al.: Molecular genetics of autosomal-recessive hereditary inclusion-body myopathy (AR-IBM) [abstract]. Ann Neurol 1997, 42:414.
55. Askanas V, Engel WK: Sporadic inclusion-body myositis and hereditary inclusion-body myopathies: diseases of oxidative stress and aging? Arch Neurol 1998, 55:915-920.
56. Bejaoui K, Hirabayashi K, Hentati F, Haines JL, Ben Hamida C, Belal S, et al.: Linkage of Miyoshi myopathy (distal autosomal recessive muscular dystrophy) locus to chromosome 2p12-14. Neurology 1995, 45:768-772.
57. Lobrinus JA, Janzer RC, Kuntzer T, Matthieu J-M, Pfend G, Goy J-J, Bogousslavsky J: Familial cardiomyopathy and distal myopathy with abnormal desmin accumulation and migration. Neuromuscul Disord 1998, 8:77-86.
58. Lippa CF, Saunders AM, Smith TW, Swearer JM, Drachman DA, Ghetti B, et al.: Familial and sporadic Alzheimer's disease: neuropathology cannot exclude a final common pathway. Neurology 1996, 46:406-412.
59. Siddique T, Nijhawan D, Hentati A: Molecular genetic basis of familial ALS. Neurology 1996, 47(4 Suppl 2):S27-S34.
60. Siddique T, Hong S, Brooks BR, Hung WY, Siddique NA, Rimmler J, et al.: X-linked dominant ALS [abstract]. Neurology 1998, 51:310.
61. Alvarez RB, Mirabella M, Sarkozi E, Engel WK, Askanas V, Heller S: Partial expression of cellular phenotype of sporadic inclusion-body myositis in autosomal dominant inclusion-body myopathy. Neurology 1996, 46:487.
62. Alvarez RB, Simmons Z, Engel WK, Askanas V: New autosomal-dominant inclusion-body myopathy (AD-IBM) with many congophilic muscle nuclei that contain paired-helical filaments (PHFs) composed of phosphorylated tau [abstract]. Neurology 1998, 50:204.
63. Sivakumar K, Semino-Mora C, Dalakas MC: An inflammatory, familial inclusion-body myositis with autoimmune features and a phenotype identical to sporadic inclusion-body myositis: studies in three families. Brain 1997, 120:653-661. Description of three families with rare late-onset muscle weakness and clinical and pathologic phenotype similar to s-IBM.
64. Garlepp MJ: Genetics of the idiopathic inflammatory myopathies. Curr Opin Rheumatol 1996, 8:514-520.
65. Hardy J: Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 1997, 20:154-159.
66. Selkoe DJ: Alzheimer's disease: genotypes, phenotype, and treatments. Science 1997, 275:630-631.
67. Hyman BT: Alzheimer's disease or Alzheimer's diseases? Clues from molecular epidemiology. Ann Neurol 1996, 40:135-136.
68. Murphy, Jr GM, Forno LS, Ellis WG, Nochlin D, Levy-Lahad E, Poorkaj P, et al.: Antibodies to presenilin proteins detect neurofibrillary tangles in Alzheimer's disease. Am J Pathol 1996, 149:1839-1846.
69. Wisniewski T, Dowjat W, Permanne B, Palha J, Kumar A, Gallo G, Frangione B: Presenilin-1 is associated with Alzheimer's disease amyloid. Am J Pathol 1997, 151:601-610.
70. Busciglio J, Hartmann H, Lorenzo A, Wong C, Buamann K, Sommer B, et al.: Neuronal localization of presenilin-1 and association with amyloid plaques and neurofibrillary tangles in Alzheimer's disease. J Neurosci 1997, 17:5101-5107.
71. Levey AI, Heilman CJ, Lah JJ, Nash NR, Rees HD, Wakai M, et al.: Presenilin-1 protein expression in familial and sporadic Alzheimer's disease. Ann Neurol 1997, 41:742-753.
72. Prusiner SB, Hsiao KK: Human prion diseases. Ann Neurol 1994, 35:385-395.
73. Askanas V, Bilak M, Engel WK, Leclerc A, Tomé F: Prion protein is strongly immunolocalized at the postsynaptic domain of human normal neuromuscular junctions. Neurosci Lett 1993, 159:111-114.
74. Sarkozi E, Askanas V, Engel WK: Abnormal accumulation of prion protein mRNA in muscle fibers of patients with sporadic inclusion-body myositis and hereditary inclusion-body myopathy. Am J Pathol 1994, 145:1280-1284.
75. Askanas V, McFerrin J, Baqué S, Alvarez RB, Sarkozi E, Engel WK: Transfer of β-amyloid precursor protein gene using adenovirus vector causes mitochondrial abnormalities in cultured normal human muscle. Proc Natl Acad Sci USA 1996, 93:1314-1319.
76. Askanas V, McFerrin J, Alvarez RB, Baqué S, Engel WK: βAPP gene transfer into cultured human muscle induces inclusion-body myositis aspects. NeuroReport 1997, 8:2155-2158.
77. Yang C-C, Alvarez RB, Engel WK, Askanas V: Increased accumulation of transcription factor NF-κB in vacuolated muscle fibers (VMFs) of inclusion-body myositis (IBM). Ann Neurol 1997, 42:451-452.
78. Mikol J, Engel AG: Inclusion-body myositis. In Myology: Basic and Clinical, vol 2. Edited by Engel AG, Franzini-Armstrong C. New York: McGraw-Hill, Inc.; 1994:1384-1398.
79. Garlepp MJ, Mastaglia FL: inclusion-body myositis. J Neurol Neurosurg Psychiatry 1996, 60:251-255.
80. Mantegazza R, Bernasconi P, Confalonieri P, Conelio F: Inflammatory myopathies and systemic disorders: a review of immunopathogenetic mechanisms and clinical features. J Neurol 1997, 244:277-287.
81. Hohlfeld R, Bender A, Engel AG: Inflammatory, nuclear, and mitochondrial abnormalities in inclusion-body myositis and inclusion-body myopathies. In Inclusion-body Myositis and Myopathies. Edited by Askanas V, Serratrice G, Engel WK. Cambridge: Cambridge University Press; 1998:263-274.
82. De Bleecker JL, Engel AG: Immunocytochemical study of CD45 T cell isoforms in inflammatory myopathies. Am J Pathol 1995, 146:1178-1187.
83. Bender A, Ernst N, Iglesias A, Dornmair K, Wekerle H, Hohlfeld R: T cell receptor repertoire in polymyositis: clonal expansion of autoaggressive CD8+ T cells. J Exp Med 1995, 181:1863-1868.
84. Bender A, Behrens L, Engel AG, Hohlfeld R: T-cell heterogeneity in muscle lesions of inclusion-body myositis. J Neuroimmunol 1998, 84:86-91.
85. Fyhr I-M, Moslemi A-R, Mosavi AA, Lindberg C, Tarkowski A, Oldfors A: Oligoclonal expansion of muscle infiltrating T cells in inclusion-body myositis. J Neuroimmunol 1997, 79:185-189.
86. Behrens L, Bender A, Johnson MA, Hohlfeld R: Cytotoxic mechanisms in inflammatory myopathies: co-expression of Fas and protective Bcl-2 in muscle fibres and inflammatory cells. Brain 1997, 120:929-938. Detailed discussion of the reasons why IBM muscle fibers do not have features of apoptosis.
87. Fyhr I-M, Oldfors A: Upregulation of Fas/Fas ligand in inclusion-body myositis. Ann Neurol 1998, 43:127-130.
88. Schneider C, Gold R, Dalakas MC, Schmied M, Lassmann H, Toyka KV, Hartung H-P: MHC class I-mediated cytotoxicity does not induce apoptosis in muscle fibers nor in inflammatory T cells: studies in patients with polymyositis, dermatomyositis and inclusion-body myositis. J Neuropathol Exp Neurol 1996, 55:1205-1209.
89. Mirabella M, Engel WK, Passinetti G, Finch CE, Askanas V: Denervation of adult human muscle fibers induces apoptosis, evidenced by fragmentation of nuclear DNA, and increased expression of the clusterin (ApoJ) gene [abstract]. Neurology 1996, 46:270.
90. Cid MC, Grau J-M, Casademont J, Tobias E, Picazo A, Coll-Vinent B, et al.: Leucocyte/endothelial cell adhesion receptors in muscle biopsies from patients with idiopathic inflammatory myopathies (IIM). Clin Exp Immunol 1996, 104:467-473.
91. Tews DS, Goebel HH: Cytokine expression profile in idiopathic inflammatory myopathies. J Neuropathol Exp Neurol 1996, 55:342-347.
92. Tews DS, Goebel HH: Expression of cell adhesion molecules in inflammatory myopathies. J Neuroimmunol 1995, 59:185-194.
93. Lundberg I, Ulfgren A-K, Nyberg P, Andersson U, Klareskog L: Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rhem 1997, 40:865-874.
94. Haginoya K, Alvarez RB, Engel WK, Askanas V: Light- and electron-microscopic immunolocalization of interleukins 1α, 1β and 6 in vacuolated muscle fibers of sporadic inclusion-body myositis (s-IBM) [abstract]. Neurology 1997, 8:126.
95. Spuler S, Engel AG: Unexpected sarcolemmal complement membrane attack complex deposits on nonnecrotic muscle fibers in muscular dystrophies. Neurology 1998, 50:41-46.
96. Pruitt JN, Showalter CJ, Engel AG: Sporadic inclusion-body myositis: counts of different types of abnormal fibers. Ann Neurol 1996, 39:139-143.
97. Hino S, Doi H: Mechanisms of HTLV-1 Transmission. In HTLV-1 and the Nervous System. Edited by Roman GC, Vernant J-C, Osame M, Hurst MJ. New York: Alan R. Liss, Inc.; 1989:495-501.
98. Beckman JS, Koppenol WH: Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 1996, 271:C1424-C1437.
99. Yang C-C, Alvarez RB, Engel WK, Askanas V: Increase of nitric oxide synthases and nitrotyrosine in inclusion-body myositis. Neuroreport 1996, 8:153-158. First evidence that nitric oxide-induced oxidative stress plays a role in the pathogenesis of a muscle disease.
100. Yang C-C, Alvarez RB, Engel WK, Heller SL, Askanas V: Nitric-oxide induced oxidative stress in autosomal recessive and dominant inclusion-body myopathies. Brain 1998, 121:1089-1097.
101. Broccolini A, Engel WK, Alvarez RB, Thomas CE, Yang C-C, Askanas V: Possible pathogenic role of malondialdehyde, a toxic product of lipid peroxidation, in inclusion-body myositis. Neurology, 1998, 50:367-368.
102. Butterfield DA: β-Amyloid-associated free radical oxidative stress and neurotoxicity: implications for Alzheimer's disease. Chem Res Toxicol 1997, 10:495-506.
103. Askanas V, Engel WK, Alvarez RB: Fourteen newly recognized proteins at the human neuromuscular junctions-and their non-junctional accumulation in inclusion-body myositis. Ann NY Acad Sci 1998, 841:28-56.